The EPS beat and narrowing loss are incremental positives, but with zero revenue and no guidance provided, the stock remains a binary event on commercial launch timing. Monitor for Early Access customer expansions and next-gen assay development milestones as catalysts.
Price Chart
Executive Summary
Nautilus Biotechnology reported Q1 2026 EPS of -$0.12, beating consensus of -$0.14 by 17.2%, with revenue still at $0 as a pre-commercialization stage company. Operating expenses fell 14% YoY to $16.1M, and net loss narrowed to $14.7M from $16.6M, while cash and investments stood at $143.4M. The beat is modest for a development-stage firm with no revenue, but the narrowing loss and cash runway extension are incremental positives.
Key Financial Metrics
Key Facts
- Q1 2026 EPS: -$0.12 vs consensus -$0.14 (17.2% beat)
- Revenue: $0 (pre-commercialization, no consensus revenue estimate)
- Operating expenses: $16.1M, down 14% YoY from $18.8M
- Net loss: $14.7M vs $16.6M YoY, narrowing by 11.5%
- Cash, cash equivalents, and investments: $143.4M as of March 31, 2026
- Initiated Iterative Mapping Early Access Program with Baylor College of Medicine
- Appointed Amber Faust as VP of Global Sales from Olink/SomaLogic
Financial Impact
EPS beat of $0.02 vs consensus, net loss improved by $1.9M YoY
Risk Factors
- No revenue and pre-commercialization stage — binary outcome on platform launch success
- Cash burn of ~$13.1M operating cash flow per quarter implies ~11 quarters of runway
- No guidance provided, limiting forward visibility
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3282599 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Apr 28, 2026 22w ago | Press Release | $2.59 $1.77 | ▼ −31.66% | ▼ −35.65% | $1.86 (−28.38%) |
Apr 28, 2026 22w ago | 8-K | $2.59 $1.77 | ▼ −31.66% | ▼ −35.65% | $1.86 (−28.38%) |
Mar 18, 2026 28w ago | Press Release | $2.74 $2.29 | ▼ −16.61% | ▼ −28.13% | $1.86 (−32.30%) |
Feb 26, 2026 31w ago | 8-K | $2.42 $2.54 | ▲ +4.96% | ▼ −2.79% | $1.86 (−23.35%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access